BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$5.08 USD
-0.07 (-1.36%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $5.09 +0.01 (0.20%) 5:04 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Industry / Sector Report
Industry : Medical - Drugs
Zacks Industry Rank
Top 36% (90 out of 252)Zacks Sector Rank
Top 25% (4 out of 16)Recommendations and Estimates
Company | Industry | SP500 | |
---|---|---|---|
Average Recommendation (1=Buy, 5=Sell) | 1.50 | 1.52 | 9.99 |
Current Quarter Estimate | -0.23 | -2.04 | 59.00 |
Year Ago Quarter Estimate | -0.28 | -0.59 | 50.37 |
Next Quarter Estimate | -0.16 | -2.00 | 60.00 |
Next Year Estimate | -0.25 | 6.92 | 250.00 |
Growth Rates
Company | Industry | SP500 | |
---|---|---|---|
This Year | 38.00 | 9.80 | 26.94 |
Next Year | 59.68 | 13.50 | 8.00 |
Last 5 Years | -386.40 | 7.20 | 9.00 |
Next 5 Years | 45.60 | 23.10 | NA |
Financials
Company | Industry | |
---|---|---|
Price/Earnings (TTM) | NA | -5.88 |
Price/Book (MRQ) | NA | 1.80 |
Price/Cash Flow (MRFY) | NA | 8.48 |
Dividend Yield | 0.00% | 0.00% |
Net Profit Margin (TTM) | -68.36% | -53.08% |
Return on Equity (TTM) | NA | -46.37% |
Debt to Equity (MRQ) | -1.79 | 0.00 |
MRQ = Most Recent Quarter
TTM = Trailing Twelve Months
MRFY = Most Recent Fiscal Year
Note: Company and S&P 500 ratios relating to share price calculated daily; all others calculated weekly or in accordance with company earnings announcement. Industry medians calculated weekly.